Roderick Verhelst

Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium.

Banque Degroof Petercam SA (Broker) (Banque Degroof-Broker) is the broker/dealer division of Banque Degroof Petercam SA, a public company headquartered in Brussels, Belgium. Banque Degroof-Broker offers order execution in different asset classes for businesses, investors and institutional clients.

Petercam SA (Broker) is the brokerage division of Petercam SA, a subsidiary of Banque Degroof SA (BSE: 698814) in Belgium. Eestablished in 1968 when family-owned brokerage houses Libert-Peterbroeck and Van Campenhout merged, the firm is headquartered in Brussels with a network of Belgian branches.

miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium.

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

Global Stem Cell Technology NV develops blood-derived mesenchymal stem cells for clinical use in horses. GST not only focusses on the preparation of stem cell samples, but also on the scientific research in order to improve currently available therapies. The company was founded by Jan H. Spaas in 2012 and is headquartered in Evergem, Belgium.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.